Results 31 to 40 of about 43,468 (306)
Patient Preference and Adherence, 2022 Oralee J Varnado,1 Janna Manjelievskaia,2 Wenyu Ye,1 Allison Perry,2 Kory Schuh,1 Richard Wenzel1 1Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; 2Watson Health Life Sciences, Research & Analytics, IBM Watson Health ...
Varnado OJ +5 more
doaj
The Journal of Headache and Pain, 2022 Background The clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients.
Sanne Hage La Cour +6 more
doaj +1 more source
Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
Expert opinion on therapeutic targets, 2020 Introduction: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a critical player in migraine pathophysiology. Excitement has grown regarding CGRP because of the development and clinical testing of drugs targeting CGRP or its ...
Anne-Sophie Wattiez, L. Sowers, A. Russo
semanticscholar +1 more source
A female-specific role for Calcitonin Gene-Related Peptide (CGRP) in rodent pain models
bioRxiv, 2021 We aimed to investigate a potentially sexually dimorphic role of Calcitonin Gene-Related Peptide (CGRP) in mouse and rat models of pain. Based on findings in migraine where CGRP has a preferential pain-promoting effect in female rodents, we hypothesized ...
C. Paige +13 more
semanticscholar +1 more source
Drug, Healthcare and Patient Safety, 2021 Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology ...
Lo Castro F, Guerzoni S, Pellesi L
doaj
Beyond CGRP: The calcitonin peptide family as targets for migraine and pain
British Journal of Pharmacology, 2021 The CGRP system has emerged as a key pharmacological target for the treatment of migraine. However, some individuals who suffer from migraine have low or no response to anti‐CGRP or other treatments, suggesting the need for additional clinical targets ...
Tayla A. Rees +3 more
semanticscholar +1 more source
Nociceptor Neurons are Involved in the Host Response to Escherichia coli Urinary Tract Infections
Journal of Inflammation Research, 2022 Zhengdong Gao,1,2,* Yaxiao Liu,1,2,* Lekai Zhang,1,2 Zizhuo Yang,1,2 Linchen Lv,1,2 Shuai Wang,1,2 Lipeng Chen,1,2 Nan Zhou,1,2 Yaofeng Zhu,1 Xuewen Jiang,1 Benkang Shi,1,2 Yan Li1,2 1Department of Urology, Qilu Hospital of Shandong University ...
Gao Z +11 more
doaj
New strategies for migraine treatment and prevention
Aktualności Neurologiczne, 2019 Migraine is a neurological disorder characterised by recurrent attacks of headache accompanied by vegetative symptoms. It is estimated that 11–12% of the world’s population suffers from migraine.
Waldemar Brola, Piotr Sobolewski
doaj +1 more source
Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo [PDF]
Frontiers in Pharmacology, 2022 Signaling through calcitonin gene-related peptide (CGRP) receptors is associated with pain, migraine, and energy expenditure. Small molecule and monoclonal antibody CGRP receptor antagonists that block endogenous CGRP action are in clinical use as anti-migraine therapies.
Aqfan Jamaluddin +13 more
openaire +3 more sources
Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine
Neuropsychiatric Disease and Treatment, 2023 Shane Root,1– 3 Kevin Ahn,3 Jack Kirsch,3 Justin L Hoskin1– 3 1Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA; 2University of Arizona School of Medicine, Phoenix, AZ, USA; 3Creighton University School of Medicine, Omaha, NE ...
Root S, Ahn K, Kirsch J, Hoskin JL
doaj